CLDX

Bullish

Barzolvolimab leaves 64% of CSU patients angioedema-free 7 months after dosing

Celldex (NASDAQ: CLDX) reported positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU) patients with angioedema, ...

Stock Titan 7 mins ago 0

Bullish

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex announced long-term results from its Phase 2 study of barzolvolimab, revealing rapid, significant, and durable improvements in angioedema for ...

Yahoo Finance Singapore 7 mins ago 0